Senti Biosciences Inc (SNTI) - Total Assets
Based on the latest financial reports, Senti Biosciences Inc (SNTI) holds total assets worth $52.69 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Senti Biosciences Inc (SNTI) balance sheet quality index to measure how much of total assets are equity-financed.
Senti Biosciences Inc - Total Assets Trend (2019–2024)
This chart illustrates how Senti Biosciences Inc's total assets have evolved over time, based on quarterly financial data. Check Senti Biosciences Inc (SNTI) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Senti Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Senti Biosciences Inc's total assets of $52.69 Million consist of 60.3% current assets and 39.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 49.3% |
| Accounts Receivable | $1.80 Million | 1.8% |
| Inventory | $335.00K | 0.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Senti Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Senti Biosciences Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Senti Biosciences Inc's current assets represent 60.3% of total assets in 2024, an increase from 52.3% in 2019.
- Cash Position: Cash and equivalents constituted 49.3% of total assets in 2024, up from 14.8% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 1.8% of total assets.
Senti Biosciences Inc Competitors by Total Assets
Key competitors of Senti Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Senti Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.51 | 1.92 | 6.52 |
| Quick Ratio | 1.51 | 1.92 | 6.52 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $6.13 Million | $8.32 Million | $26.84 Million |
Senti Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Senti Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.69 |
| Latest Market Cap to Assets Ratio | 0.22 |
| Asset Growth Rate (YoY) | -18.1% |
| Total Assets | $97.84 Million |
| Market Capitalization | $21.87 Million USD |
Valuation Analysis
Below Book Valuation: The market values Senti Biosciences Inc's assets below their book value (0.22x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Senti Biosciences Inc's assets decreased by 18.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Senti Biosciences Inc (2019–2024)
The table below shows the annual total assets of Senti Biosciences Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $97.84 Million | -18.11% |
| 2023-12-31 | $119.48 Million | -33.91% |
| 2022-12-31 | $180.79 Million | +86.96% |
| 2021-12-31 | $96.70 Million | +100.02% |
| 2020-12-31 | $48.34 Million | +34.88% |
| 2019-12-31 | $35.84 Million | -- |
About Senti Biosciences Inc
Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications w… Read more